I’m bumping this post from September 2021, as it still stands. This was PRE-cardioprotection discovery, which is as we know an enormous opportunity.
Therefore, even with these numbers below, it’s entirely possible that I undercooked it by ~50% total addressable market.
FTO underpins most cancers. Most SoC drugs damage hearts. We interoperate with those drugs. We hold two keys here - and are looking at new molecules that go Beyond Zantrene (Pillar 3). If you don’t think the potential of a blockbuster, history-making, market disrupting figure is on the table, you need to go back and do some rereading.
Big Pharma will want this. Small Pharma will want this. Clinicians and insurance companies will want this.
There will be a bidding war.
The final price will surely shock the market as Keytruda did. It has that much potential.
———
“There are some great valuation figures floating around that most have seen from Wombat and Mason (and others) - but based on evidence and markets we'll be disrupting, even the high-end figures are conservatively projected. Again, expect an enormous reevaluation by these guys once the pre-clins are wrapped up and we have efficacy data.
It is not an exaggeration to say RAC is working toward making Zantrenethe next Keytruda. If FTO is proven effective, we may dwarf the figure Keytruda makes each year (projected to be $22.2bn annually by 2025), as we will improve so many types of treatments. I know that's hard to imagine right now, but the potential is there. Remember that valuation is roughly 4-5x EBITDA.
So for the sake of argument: 4-5x $22bn, with $USD100 per share roughly calculated @ $USD21bn = $88bn to $110bn, or USD$400-500 per share.
Now that's not to say we'll achieve this, but that's the hand-on-heart valuation as it stands right now in my eyes. I could see RAC offering a discount, or dividing the Zantrene property up into different licensed elements etc etc. We might or might not go down the partnership path, we might or might not be successful in one or all aspects. However, we are First, Best, Only in Class - and this space is absolutely being sought after by Big Pharma, who are cashed up like crazy after COVID. So we are in an enviable position.”
Expand
(20min delay)